Chronic kidney disease: Implications for the perioperative period

Minerva Anestesiologica

Volumn 76, Issue 9, 2010, Pages 725-736

  Eilers, H ^a   Liu, K D ^a   Gruber, A ^a   Niemann, C U ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic; Early diagnosis; Kidney failure; Morbidity; Mortality

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CADMIUM; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; FENOLDOPAM; FUROSEMIDE; INSULIN; IONIC CONTRAST MEDIUM; IRBESARTAN; LEAD; MANNITOL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PLACEBO; SODIUM CHLORIDE; STEROID; UNINDEXED DRUG;

ABDOMINAL AORTA ANEURYSM; ANEURYSM SURGERY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS SURGERY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DRUG MEGADOSE; ENDOVASCULAR SURGERY; GLYCEMIC CONTROL; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LABORATORY TEST; LAPAROSCOPIC SURGERY; LOW DRUG DOSE; MORTALITY; NEPHROTOXICITY; NONHUMAN; OFF PUMP CORONARY SURGERY; PATHOPHYSIOLOGY; PATIENT SAFETY; PERIOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PREVALENCE; PROTEINURIA; RENAL PROTECTION; REVIEW; SURGICAL RISK; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA ANEURYSM;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 77957941179     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047
3. Palevsky PM: Perioperative management of patients with chronic kidney disease or ESRD. Best Pract Res Clin Anaesthesiol 2004;18:129-144.
4. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
5. Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 2002;39:930-936.
6. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16: 3365-3370.
7. Chertow GM, Soroko SH, Paganini EP, Cho KC, Himmelfarb J, Ikizler TA et al. Mortality after acute renal failure:Models for prognostic stratification and risk adjustment. Kidney Int 2006;70:1120-1126.
8. Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051-2058.
9. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S et al. Acute renal failure in critically ill patients:a multinational, multicenter study. JAMA 2005;294:813-818.
10. Novis BK, Roizen MF, Aronson S, Thisted RA: Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994;78:143-149.
11. Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R. Protective importance of the myogenic response in the renal circulation. Hypertension 2009;54:393-398.
12. Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006;17:S98-S103.
13. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-762.
14. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003;41:1341-1345.
15. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
16. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong P et al. Progression of chronic kidney disease:the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition:a patient-level meta-analysis. Ann Intern Med 2003;139:244-252.
17. Deferrari G, Ravera M, Berruti V. Treatment of diabetic nephropathy in its early stages. Diabetes Metab Res Rev 2003;19:101-114.
18. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial:clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-3037
19. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-287
20. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents:a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-1974.
21. Kidney Disease Outcomes Quality Initiative: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43: S1-S290.
22. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-2179.
23. Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-850.
24. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043-1049.
25. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998;88:7-17.
26. Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713-1720.
27. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-1794.
28. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial):a randomised controlled trial. Lancet 2008;371: 1839-1847.
29. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006;70:1905-1913.
30. Kotanko P: Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood Purif 2006;24: 95-99.
31. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125: 1007-1021.
32. Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology 2005;103:687-694.
33. Schmeltz LR, DeSantis AJ, Thiyagarajan V, Schmidt K, O'Shea-Mahler E, Johnson D et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care 2007;30:823-828.
34. Turina M, Miller FN, Tucker CF, Polk HC. Short-term hyperglycemia in surgical patients and a study of related cellular mechanisms. Ann Surg 2006;243: 845-851;discussion 851-853.
35. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al.:Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297.
36. Lipshutz AK, Gropper MA: Perioperative glycemic control:an evidence-based review. Anesthesiology 2009;110:408-421.
37. Westhuyzen J: Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci 2006;36:387-394.
38. Shlipak MG, Praught ML, Sarnak MJ: Update on cystatin C:new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006;15:270-275.
39. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
40. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA et al. Cystatin C and mortality risk in the elderly:the health, aging, and body composition study. J Am Soc Nephrol 2006;17:254-261.
41. Herget-Rosenthal S, Marggraf G, Husing J, Göring F, Pietruck F, Janssen O et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004;66:1115-1122.
42. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin:a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24: 307-315.
43. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073-3082.
44. Niemann CU, Walia A, Waldman J, Davio M, Roberts JP, Hirose R et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009;15:1852-1860.
45. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-1238.
46. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006;6:1639-1645.
47. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006;105: 485-491.
48. McIlroy DR, Wagener G, Lee HT: Neutrophil Gelatinase-Associated Lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 2010;5:211-219.
49. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343-348.
50. Zanardo G, Michielon P, Paccagnella A, Rosi P, Caló M, Salandin V et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg 1994;107:1489-1495.
51. Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery:results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006;113:1063-1070.
52. Devbhandari MP, Duncan AJ, Grayson AD, Fabri BM, Keenan DJ, Bridgewater B et al. Effect of risk-adjusted, nondialysis- dependent renal dysfunction on mortality and morbidity following coronary artery bypass surgery:a multi-centre study. Eur J Cardiothorac Surg 2006;29:964-970.
53. Hillis GS, Croal BL, Buchan KG, El-Shafei H, Gibson G, Jeffrey RR et al. Renal function and outcome from coronary artery bypass grafting:impact on mortality after a 2.3-year follow- up. Circulation 2006;113:1056-1062.
54. Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization:the Arterial Revascularization Therapies Study (ARTS). Am Heart J 2005;149:512-519.
55. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004;15:1597-1605.
56. Winkelmayer WC, Levin R, Avorn J. Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgery. Am J Kidney Dis 2003;41:84-89.
57. Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005;16:195-200.
58. Cheng DC, Bainbridge D, Martin JE, Novick RJ. Does off pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology 2005;102:188-203.
59. Chukwuemeka A, Weisel A, Maganti M, Nette AF, Wijeysundera DN, Beattie WS et al. Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery:a propensity score analysis. Ann Thorac Surg 2005;80:2148-153.
60. Weerasinghe A, Athanasiou T, Al-Ruzzeh S, Casula R, Tekkis PP, Amrani M et al. Functional renal outcome in on-pump and off-pump coronary revascularization: a propensity-based analysis. Ann Thorac Surg 2005;79:1577-1583.
61. Wijeysundera DN, Karkouti K, Beattie WS, Rao V, Ivanov J: Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. Anesthesiology 2006;104:65-72.
62. Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F et al. Preoperative renal risk stratification. Circulation 1997;95:878-884.
63. Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP: A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005;16:162-168
64. Park B, Danes S, Drezner AD, Gallagher J, Allmendinger P, Lowe R et al. Endovascular abdominal aortic aneurysm repair at hartford hospital:a six year experience. Conn Med 2006;70:357-362.
65. Wald R, Waikar SS, Liangos O, Pereira BJ, Chertow GM, Jaber BL. Acute renal failure after endovascular vs open repair of abdominal aortic aneurysm. J Vasc Surg 2006;43: 460-466;discussion 466.
66. Johnson ML, Bush RL, Collins TC, Lin PH, Liles DR, Henderson WG et al. Propensity score analysis in observational studies:outcomes after abdominal aortic aneurysm repair. Am J Surg 2006;192:336-343.
67. Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 2005;352:2398-2405.
68. Sicard GA, Zwolak RM, Sidawy AN, White RA, Siami FS: Endovascular abdominal aortic aneurysm repair:longterm outcome measures in patients at high-risk for open surgery. J Vasc Surg 2006;44:229-236.
69. Pannu N, Wiebe N, Tonelli M: Prophylaxis strategies for contrast-induced nephropathy. Jama 2006;295:2765-2779
70. Pérez J, Taurá P, Rueda J, Balust J, Anglada T, Beltran J et al. Role of dopamine in renal dysfunction during laparoscopic surgery. Surg Endosc 2002;16:1297-1301.
71. Sear JW: Kidney dysfunction in the postoperative period. Br J Anaesth 2005;95: 20-32.
72. Koppert W, Frotsch K, Huzurudin N, Koppert W, Frötsch K, Huzurudin N, Böswald W, Griessinger N, Weisbach V et al. The effects of paracetamol and parecoxib on kidney function in elderly patients undergoing orthopedic surgery. Anesth Analg 2006;103:1170-1176.
73. Zacharias M, Gilmore IC, Herbison GP, Sivalingam P, Walker RJ. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2005: CD003590.
74. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW: Renal insufficiency and heart failure:prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-1009
75. Bruch C, Rothenburger M, Gotzmann M, Wichter T, Scheld HH, Breithardt G et al. Chronic kidney disease in patients with chronic heart failure - Impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol 2007;118:375-380.
76. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
77. Knos GB, Berry AJ, Isaacson IJ, Weitz FI: Intraoperative urinary output and postoperative blood urea nitrogen and creatinine levels in patients undergoing aortic reconstructive surgery. J Clin Anesth 1989;1:181-185.
78. Pull ter Gunne AJ, Bruining HA, Obertop H: Haemodynamics and 'optimal' hydration in aortic cross clamping. Neth J Surg 1990;42:113-117.
79. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
80. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy:randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
81. Reid F, Lobo DN, Williams RN, Rowlands BJ, Allison SP: (Ab)normal saline and physiological Hartmann's solution:a randomized double-blind crossover study. Clin Sci (Lond) 2003;104:17-24.
82. Schenarts PJ, Sagraves SG, Bard MR, Toschlog EA, Goettler CE, Newell MA et al. Low-dose dopamine:a physiologically based review. Curr Surg 2006;63:219-225.
83. Carcoana OV, Mathew JP, Davis E, Byrne DW, Hayslett JP, Hines RL et al. Mannitol and dopamine in patients undergoing cardiopulmonary bypass:a randomized clinical trial. Anesth Analg 2003;97:1222-1229.
84. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-2143.
85. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure:a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007;49:56-68.
86. Aravindan N, Aravindan S, Riedel BJ, Weng HR, Shaw AD: Furosemide prevents apoptosis and associated gene expression in a rat model of surgical ischemic acute renal failure. Ren Fail 2007;29:399-407.
87. Ho KM, Sheridan DJ: Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006;333:420.
88. Davis A, Gooch I: Best evidence topic report. The use of loop diuretics in acute renal failure in critically ill patients to reduce mortality, maintain renal function, or avoid the requirements for renal support. Emerg Med J 2006;23: 569-570.
89. Schnuelle P, Johannes van; Perioperative fluid management in renal transplantation: A narrative review of the literature. Transpl Int 2006;19:947-959.
90. Burke TJ, Arnold PE, Schrier RW: Prevention of ischemic acute renal failure with impermeant solutes. Am J Physiol 1983;244:F646-F649.
91. Zager RA, Mahan J, Merola AJ: Effects of mannitol on the postischemic kidney. Biochemical, functional, and morphologic assessments. Lab Invest 1985;53:433-442.
92. Nicholson ML, Baker DM, Hopkinson BR, Wenham PW: Randomized controlled trial of the effect of mannitol on renal reperfusion injury during aortic aneurysm surgery. Br J Surg 1996;83:1230-1203
93. Ryckwaert F, Colson P, Ribstein J, Boccara G, Guillon G: Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction. Br J Anaesth 2001;86: 169-175.
94. Joannidis M, Schmid M, Wiedermann CJ: Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate:a meta-analysis. Wien Klin Wochenschr 2008;120:742-748.
95. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
96. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-410.
97. Ristikankare A, Kuitunen T, Kuitunen A, Uotila L, Vento A, Suojaranta-Ylinen R et al. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006;97:611-616.
98. Hynninen MS, Niemi TT, Pöyhiä R, Raininko EI, Salmenperä MT, Lepäntalo MJ et al. N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial. Anesth Analg 2006;102:1638-1645.
99. Perazella MA, Khan S: Increased mortality in chronic kidney disease: a call to action. Am J Med Sci 2006;331:150-153.
100. O'Connor AS, Schelling JR. Diabetes and the kidney. Am J Kidney Dis 2005;46:766-773.
101. Caramori ML, Mauer M. Pathogenesis and Pathophysiology of Diabetic Nephropathy, Primer on Kidney Diseases. Edited by Greenberg A. Philadelphia, PA, Elsevier, 2005, pp 241-248
102. McGowan TA, Ziyadeh FN: Clinical Course and Management of Diabetic Nephropathy, Primer on Kidney Diseases. Edited by Greenberg A. Philadelphia, PA, Elsevier, 2005, pp 249-255
103. Jennette JC, Falk RJ: Glomerular Clinicopathologic Syndromes, Primer on Kidney Diseases. Edited by Greenberg A. Philadelphia, PA: Elsevier; 2005. p. 150-164.
104. Cattran DC: Membranous Nephropathy, Primer on Kidney Diseases. Edited by Greenberg A. Philadelphia, PA: Elsevier; 2005. p. 183-190.
105. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA, Jr., Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000;35:878-883.
106. Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl 2003;83:S43-S49.
107. Markowitz GS, Perazella MA: Drug-induced renal failure:a focus on tubulointerstitial disease. Clin Chim Acta 2005; 351:31-47.
108. Rossert J: Drug-induced acute interstitial nephritis. Kidney Int 2001;60: 804-817.
109. Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis 1994;24:130-141.
110. Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. J Hypertens 1999;17:309-317.
111. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
112. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.